Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
Goldman Sachs analyst Salveen Richter says big pharma is shopping in China biotech as $440 billion in drugs lose patents.
Opent in een nieuw tabblad. Via Cryptopage meten we de klik voor statistieken.
Partner